ArticleJournal of gastroenterology2020
Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-naïve cohort of junior high school students in Japan.
Article in Journal of gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06811207 (Comparison of the Efficacies of Two Novel Dose Dual Therapies in the First-line Helicobacter Pylori Eradication), which is not on this map. Cited by 38 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparison of the Efficacies of Two Novel Dose Dual Therapies in the First-line Helicobacter Pylori Eradication
Who cites it
38 citing papers in PubMed, 6 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- Assessing the non-inferiority of a 10-day compared with a 14-day vonoprazan-amoxicillin dual therapy regimen for H. pylori eradication: a systematic review and meta-analysis.BMC infectious diseases · 2026Pooled it
- Efficacy and safety of vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for patients withFrontiers in microbiology · 2025Pooled it
- Global status and trends of gastric cancer and gastric microbiota research: a bibliometric analysis.Frontiers in microbiology · 2024Pooled it
- The efficacy and safety of vonoprazan-amoxicillin dual therapy in eradicating Helicobacter pylori: a systematic review and meta-analysis.European journal of medical research · 2023Pooled it
- Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis.Digestion · 2023Pooled it
- Vonoprazan-amoxicillin dual therapy forSaudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationPooled it
- Regional multi-center randomized trial of three vonoprazan-amoxicillin dosing regimens forWorld journal of gastroenterology · 2025Trial
- Effectiveness and safety of vonoprazan and amoxicillin dual regimen with Saccharomyces boulardii supplements on eradication of Helicobacter pylori.BMC gastroenterology · 2024Trial
- Comparison of vonoprazan-based with rabeprazole-based dual therapy for treatment-naive patients of Helicobacter pylori infection: a prospective, multi-center, randomized controlled study.Journal of gastroenterology · 2023Trial
- Safety and effectiveness of vonoprazan-based rescue therapy forWorld journal of gastroenterology · 2023Trial
- A Modified 14-Day Dual Therapy with Vonoprazan and Amoxicillin Amplified the Advantages Over Conventional Therapies for Eradication ofInfection and drug resistance · 2023Trial
- Fourteen-day vonoprazan and low- or high-dose amoxicillin dual therapy for eradicatingFrontiers in immunology · 2022Trial
- Altered Gut Microbiota and Short-Chain Fatty Acids After Vonoprazan-Amoxicillin Dual Therapy forFrontiers in cellular and infection microbiology · 2022Trial
- Vonoprazan-based bismuth quadruple therapy for first-line Helicobacter pylori eradication: A real-world, retrospective study.Medicine · 2026Article
- Real-world effectiveness of vonoprazan-based regimen versus rabeprazole-based dual therapy forFrontiers in medicine · 2026Article
- Potassium-competitive acid blockers forFrontiers in cellular and infection microbiology · 2026Review
- Update on the Management of Helicobacter pylori Infection in Children and Adolescents.Current gastroenterology reports · 2025Review
- Role of Vonoprazan-Amoxicillin Dual Therapy in Pediatric RefractoryACG case reports journal · 2025Article
- The interval of rescue treatment does not affect the efficacy and safety of Helicobacter pylori eradication: A prospective multicenter observational study.Chinese medical journal · 2025Observational
- Long-term evaluation of Helicobacter pylori screening in school health checkups: an 11-year study in Japan.Journal of gastroenterology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough 7-day triple therapy, consisting of vonoprazan, amoxicillin (AMO), and clarithromycin (CLA), is recommended for Helicobacter pylori (H. pylori) eradication in adults. However, the importance of reducing antibiotic use in pediatric patients is well recognized. Therefore, our aim was to compare the effectiveness and safety of vonoprazan and AMO (VA) dual therapy to vonoprazan-based (VAC) triple therapy for H. pylori eradication in a cohort of treatment-naïve junior high school students in Japan.
methodsThis was a prospective observational study of second-year junior high-school students in Yurihonjo and Nikaho Cities, Japan. Between 2015 and 2017, 161 students were treated with VAC-triple therapy (20 mg vonoprazan, 750 mg AMO, and 200 mg CLA, twice a day for 7 days), while 60 students were treated with VA-dual therapy (20 mg vonoprazan and 750 mg AMO, twice a day for 7 days) since 2018. The success rate of H. pylori eradication and drug-related adverse events were compared between the two therapy groups. Intention-to-treat (ITT) and per-protocol (PP) analyses were performed.
resultsGroups were comparable at baseline. The ITT and PP eradication rates were 85.0% (95% confidence interval [CI] 75.8-94.2%) and 86.4% (95% CI 77.4-95.5%), respectively, with VA-dual therapy and 82.0% (95% CI 76.0%-87.9%) and 84.1% (95% CI 78.3-89.8%), respectively, with VAC-triple therapy. VA-dual therapy was non-inferior to VAC-triple therapy (ITT, p = 0.018; PP, p = 0.020). The adverse event rate was 10.0% with VA-dual therapy and 19.8% with VAC-triple therapy (p = 0.108).
conclusionsThe effectiveness of VA-dual therapy was comparable to that of VAC-triple therapy in H. pylori treatment-naïve junior high school students, while reducing the use of antibiotics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.